Cited by 118Blood Pressure and Hypertension StudiesHeart Failure Treatment and ManagementSodium Intake and Health

Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial

Open access
Upadhya, Bharathi, Rocco, Michael, Lewis, Cora E., Oparil, Suzanne, Lovato, Laura C., Cushman, William C., Bates, Jeffrey T., Bello, Natalie A. +9 more·2017·Circulation: Heart Failure

Abstract

Background— Acute decompensated heart failure (ADHF) was a frequent common outcome in SPRINT (Systolic Blood Pressure Intervention Trial). We examined whether there was differential reduction in ADHF events from intensive blood pressure [BP] treatment among the 6 key, prespecified subgroups in SPRINT: age ≥75 years, prior cardiovascular disease, chronic kidney disease, women, black race, and 3 levels of baseline systolic BP (≤132 versus >132 to <145 versus ≥145 mm Hg). Methods and Results— ADHF was defined as hospitalization for ADHF, confirmed and formally adjudicated by a blinded events committee using standardized protocols. At 3.29 years follow-up, there were 103 ADHF events (2.2%) among 4683 standard arm participants and 65 ADHF events (1.4%) among 4678 intensive arm participants (Cox proportional hazards ratio, 0.63; 95% confidence interval, 0.46–0.85; P value =0.003). In multivariable analyses, including treatment arm, baseline covariates that were significant predictors for ADHF included chronic kidney disease, cardiovascular disease, age≥75 years, body mass index, and higher systolic BP. The beneficial effect of the intervention on incident ADHF was consistent across all prespecified subgroups. Participants who had incident ADHF had markedly increased risk of subsequent cardiovascular events, including a 27-fold increase ( P <0.001) in cardiovascular death. Conclusions— Targeting a systolic BP<120 mm Hg, compared with <140 mm Hg, significantly reduced ADHF events, and the benefit was similar across all key, prespecified subgroups. Participants who developed ADHF had markedly increased risk for subsequent cardiovascular events and death, highlighting the importance of strategies aimed at prevention of ADHF, especially intensive BP reduction. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01206062

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.116.003613

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the SPRINT trial, intensive treatment of hypertension decreased the risk for development of incident heart failure by 36%.

    “Similarly, in the SPRINT trial, intensive treatment of hypertension decreased the risk for development of incident heart failure by 36% (277).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [277]

    The Conclusions report a 36% reduction in acute decompensated heart failure (ADHF) with intensive blood-pressure treatment in SPRINT. The Methods (Study Outcomes) say all ADHF events were incident heart-failure events, but define them as events requiring hospital or emergency-department treatment. The claim broadens that specific outcome to incident heart failure generally. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • In the SPRINT trial, the risk for development of incident heart failure decreased by 36%.

    “Intensive treatment of hypertension in people with diabetes in the BPROAD trial led to a 34% reduction in treatment or hospitalization for heart failure (HR 0.66, 95% CI 0.41–1.04), a finding that parallels observations from the SPRINT trial where the risk for development of incident heart failure decreased by 36% (42,274).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [274]

    The Conclusions report a 36% reduction in acute decompensated heart failure (ADHF) with intensive blood-pressure treatment in SPRINT. The Discussion says new outpatient heart failure was not counted, so the result does not establish a 36% reduction in incident heart failure overall. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • In the BPROAD trial, intensive treatment of hypertension in people with diabetes led to a 34% reduction in treatment or hospitalization for heart failure (HR 0.66, 95% CI 0.41-1.04).

    “Intensive treatment of hypertension in people with diabetes in the BPROAD trial led to a 34% reduction in treatment or hospitalization for heart failure (HR 0.66, 95% CI 0.41–1.04), a finding that parallels observations from the SPRINT trial where the risk for development of incident heart failure decreased by 36% (42,274).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 46 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Upadhya, B., Rocco, M., Lewis, C. E., Oparil, S., Lovato, L. C., Cushman, W. C., Bates, J. T., Bello, N. A., Aurigemma, G., Fine, L. J., Johnson, K. C., Rodriguez, C. J., Raj, D. S., Rastogi, A., Tamariz, L., Wiggers, A., & Kitzman, D. W.
Affiliations
  • University of Alabama (US)
  • From the Cardiovascular Medicine Section (B.U., C.J.R., D.W.K.), Nephrology Section, Department of Internal Medicine (M.R.), and Biostatistics (L.C.L.), Wake Forest School of Medicine, Winston-Salem, NC; Division of Preventive Medicine (C.E.L.) and Division of Cardiovascular Disease (S.O.), Department of Medicine, University of Alabama, Birmingham; Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, TN (W.C.C.); Michael E. DeBakey Veterans Affairs Medical Center and Baylor College...
Venue
Circulation: Heart Failure
Published
2017-04
Volume
10
Issue
4
ISSN
  • 1941-3289 (ISSN-L)
  • 1941-3297
OpenAlex
W2601765095
Cited by
118
References
46
Citations by year
2026: 5 · 2025: 14 · 2024: 8 · 2023: 8 · 2022: 16 · 2021: 15 · 2020: 20 · 2019: 19 · 2018: 9 · 2017: 3 · 2016: 1
FWCI
10.79
Type
journal article
Language
en
Open access
Locations
  • Circulation Heart Failure (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • Amgen
  • Gilead Sciences
  • University of California
  • George Washington University
  • University of Michigan
  • University of Florida
  • University of Utah
  • University of Pittsburgh
  • National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR000073, UL1TR001064, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
  • University of Illinois at Urbana-Champaign
  • Relypsa
  • National Institute on Aging (R01AG020583, R01AG018915, R01AG045551, P30AG021332)
  • National Heart, Lung, and Blood Institute (R01HL107257, HHSN268200900040C, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
  • National Institute of General Medical Sciences (P30GM103337)
  • National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords
acute decompensated heart failure, intensive blood pressure lowering, systolic blood pressure, SPRINT trial, cardiovascular mortality, chronic kidney disease, cardiovascular disease, older adults, race and sex differences, subgroup analysis
MeSH terms
Aged, Aged, 80 and over, Antihypertensive Agents, Blood Pressure, Female, Heart Failure, Hospitalization, Humans, Hypertension, Male, Middle Aged, Risk Factors, Time Factors, Comorbidity, Multivariate Analysis, Chi-Square Distribution, Proportional Hazards Models, Treatment Outcome, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review